Back

Is left atrial appendage closure replacing oral anticoagulation? - discussion

30 August 2026 (08:45 - 09:00)
Organised by: Logo
Congress Presentation Part of: Great Debates: atrial fibrillation without oral anticoagulation - future vision or dangerous illusion? Stroke Prevention ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

5 More presentations in this session

Presentation thumbnail
Is left atrial appendage closure replacing oral anticoagulation?: pro
Doctor D. Nair (Jonesboro, US)
Slides Video
Presentation thumbnail
Is left atrial appendage closure replacing oral anticoagulation?: con
Professor P. Kirchhof (Hamburg, DE)
Slides Video
Presentation thumbnail
Can we stop oral anticoagulation after successful atrial fibrillation ablation?: pro
Professor B. Joung (Seoul, KR)
Slides Video
Presentation thumbnail
Can we stop oral anticoagulation after successful atrial fibrillation ablation?: con
Professor I. Van Gelder (Groningen, NL)
Slides Video
Presentation thumbnail
Can we stop oral anticoagulation after successful atrial fibrillation ablation? - discussion
Video

Access the full session

Session thumbnail
Great Debates: atrial fibrillation without oral anticoagulation - future vision or dangerous illusion?
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 08:45 CET
You may be interested in
thumbnail
Congress Session
Debates in atrial fibrillation ablation (1)
8 April 2024
thumbnail
Congress Presentation
The floor is yours: bring your questions on triggered atrial fibrillation, device-detected atrial fibrillation, and atrial fibrillation burden - expert panel
30 August 2026
thumbnail
Congress Presentation
Great direct-acting oral anticoagulants debate: start and stay vs time to switch
30 August 2026
thumbnail
Congress Presentation
Contemporary management of cardiac arrhythmias: strategies and innovations to optimise clinical outcomes
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources